Sichuan Goldstone subsidiary Asia Pharmaceutical plans to increase its capital by 200 million yuan to Yak Pharmaceutical.
Jinshiya Medicine (300434.SZ) announced that, in accordance with the company's development strategy and its wholly-owned subsidiary Zhejiang Ya...
Sichuan Goldstone (300434.SZ) announced that, according to the company's development strategy and the business needs of its wholly-owned subsidiary Zhejiang Yake Pharmaceutical Co., Ltd. ("Yake Pharmaceutical"), its wholly-owned subsidiary Hainan Asia Pharmaceutical Co., Ltd. ("Asia Pharmaceutical") plans to increase its capital by RMB 200 million to Yake Pharmaceutical using its own funds. After this capital increase is completed, Yake Pharmaceutical's registered capital will increase from RMB 1.5 billion to RMB 3.5 billion.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
